The Food and Drug Administration has reached an agreement with the brand-name drug industry on a five-year plan that will increase industry fees paid to the agency by about 6% and continue to fund the expansion of new drug approvals, according to people familiar with the talks. The relatively smooth negotiations between the agency and the prescription-drug industry stand in contrast to the contentious talks between the FDA and the medical-device industry.
